Antiretroviral News and Research

RSS

VGTI, OHSU's new vaccine candidate may fight against HIV

Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute has developed a vaccine candidate in non-human primates that may eventually lead to a vaccine against Human Immunodeficiency Virus.

12 May 2011

Study: XMRV retrovirus is not present in chronic fatigue syndrome patients

New findings from University of Utah School of Medicine researchers show that the retrovirus called XMRV is not present in the blood of patients who have chronic fatigue syndrome.

5 May 2011

AHF cautions against fast track FDA-approval for expanded use of Gilead’s Truvada

During its quarterly meeting over the weekend, The Board of Directors of the AIDS Healthcare Foundation (AHF) adopted a resolution cautioning Gilead Sciences against seeking fast track FDA-approval for the expanded use of its best selling AIDS treatment, Truvada, as a possible form of pre-exposure prophylaxis (PrEP) to prevent the transmission of HIV.

4 May 2011

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca announced today that the U.S. Food and Drug Administration has approved the use of NEXIUM I.V. for Injection for children ages greater than 1 month old for the short-term treatment of gastroesophageal reflux disease with erosive esophagitis when oral therapy is not possible or appropriate.

3 May 2011

HIV/AIDS research in Africa

Nowhere in the world has the AIDS/HIV pandemic cut a greater swath of devastation than in sub-Saharan Africa, where two-thirds of all people infected with the virus reside. As Barbara Smith, PhD, RN, FAAN, discovered firsthand, no segment of society there has been left unscathed.

30 Apr 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.

30 Apr 2011

MSF letter criticizes Johnson & Johnson for not joining Medicines Patent Pool

Medecins Sans Frontieres recently sent a letter to Johnson & Johnson criticizing the pharmaceutical company for "refusing to make patents on three HIV drugs available to a program that would reduce the cost of the medicines in developing countries," the Star-Ledger reports.

27 Apr 2011

African-American couples with HIV can benefit from health promotion interventions

Interventions to promote healthy behaviors, including eating more fruits and vegetables, increasing physical activity, and participating in cancer screenings, as well as prevention of HIV/sexually transmitted diseases, appear beneficial for African-American couples who are at high risk for chronic diseases, especially if one of the individuals is living with HIV.

26 Apr 2011

Study: More couple-based HIV counseling needed in South Africa

A new study of sexual risk behaviors within long-term couples in South Africa finds that HIV-positive people take almost as much risk in their sexual behavior when they know their partner is HIV-negative or don't know their status, as when they know their partner is already infected.

26 Apr 2011

Study: HIV infection linked to increased risk of heart failure

Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the April 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Apr 2011

Study questions suitability of anti-retroviral drugs for the young

According to a new major study one in eight children born with HIV becomes resistant to the three main classes of drugs used to suppress the virus within five years of starting treatment. This is the first major study that looks at drug resistance in 1,000 European children born with HIV. It raises questions about the suitability of anti-retroviral drugs for the young.

25 Apr 2011

Rate of antiretroviral virological failure higher among children living with HIV/AIDS than adults, study finds

One in eight children living with HIV/AIDS "experiences triple-class virological failure - meaning the virus becomes resistant to multiple drugs - within five years of starting antiretroviral treatment," according to a study published Wednesday in the Lancet, HealthDay News/MSN reports. The "failure rate is higher than in adults and highlights the challenge of maintaining viral load suppression in young patients who begin antiretroviral therapy so early in life, the researchers said," according to the news service (Preidt, 4/19).

21 Apr 2011

Study shows possibility of women living with AIDS to breastfeed with lower risk

In low-income countries, 1.4 million women are living with the Aids virus. If no prevention measures are taken, the risk for future mothers of transmitting HIV to their child in utero, during delivery or when breastfeeding is 35%.

20 Apr 2011

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.

20 Apr 2011

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

On the heels of Centers for Disease Control announcement earlier today that an ongoing study of the use of Gilead's top selling AIDS treatment, Truvada, as a possible form of pre-exposure prophylaxis for HIV prevention in women is being abruptly halted because the, "…trial could not demonstrate efficacy," the AIDS Healthcare Foundation renewed its call on Gilead Sciences to slow its fast track pursuit of its application for FDA approval of use of its AIDS drug as a possible form of HIV prevention.

20 Apr 2011

African AIDS drug trial stopped prematurely

One of the studies in three African countries where women were given an AIDS drug to prevent HIV infection is being stopped because the project is not working, researchers said Monday. These women on the trial were taking a daily dose of the drug Truvada or a look-alike placebo pill and had an equal chance of becoming infected. The ones taking Truvada were expected to have had a much lower infection rate.

19 Apr 2011

AHF commends U.S. Congress for strong bipartisan commitment to AIDS

AIDS Healthcare Foundation today commended the United States Congress for showing a strong bipartisan commitment to AIDS in passing the fiscal year 2011 budget earlier this afternoon, a budget that despite severe cost-cutting mentality in Washington, included a $48 million overall increase in the $883 million allocated for the nation's AIDS Drug Assistance Program, a network of federal and state funded programs that provide life-saving HIV treatments to low income, uninsured, and underinsured individuals living with HIV/AIDS nationwide.

16 Apr 2011

Increased risk of virologic failure associated with NNRTI-based regimens in HIV-1 drug resistance mutations

An analysis of data from 10 studies indicates that the presence of low frequency (also called "minority") human immunodeficiency virus type 1 (HIV-1) drug resistance mutations, particularly those involving nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, are significantly associated with an increased risk of first-line antiretroviral treatment failure, according to an article in the April 6 issue of JAMA.

6 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

AHF launches public tribute to Hollywood legend with billboards around Los Angeles

This week, AIDS Healthcare Foundation, the largest global AIDS organization, launched a public tribute to Hollywood legend Elizabeth Taylor with a number of billboards around Los Angeles commemorating her contribution to the AIDS fight.

2 Apr 2011

Antiretroviral News and Research

VGTI, OHSU's new vaccine candidate may fight against HIV

Study: XMRV retrovirus is not present in chronic fatigue syndrome patients

AHF cautions against fast track FDA-approval for expanded use of Gilead’s Truvada

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

HIV/AIDS research in Africa

Merck first quarter sales increase 1% to $11.6 billion for 2011

MSF letter criticizes Johnson & Johnson for not joining Medicines Patent Pool

African-American couples with HIV can benefit from health promotion interventions

Study: More couple-based HIV counseling needed in South Africa

Study: HIV infection linked to increased risk of heart failure

Study questions suitability of anti-retroviral drugs for the young

Rate of antiretroviral virological failure higher among children living with HIV/AIDS than adults, study finds

Study shows possibility of women living with AIDS to breastfeed with lower risk

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

African AIDS drug trial stopped prematurely

AHF commends U.S. Congress for strong bipartisan commitment to AIDS

Increased risk of virologic failure associated with NNRTI-based regimens in HIV-1 drug resistance mutations

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

AHF launches public tribute to Hollywood legend with billboards around Los Angeles

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News